Seeking Monogenic Targets for RNA Interference-Based Therapy

Benitec Biopharma is an American biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy for the goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration.

Benitec Biopharma are seeking research focused on the identification of monogenic targets (both dominant and recessive) that can be downregulated by expressed RNAi and replaced with a RNAi insensitive transgene.

Approaches of Interest

- Broad interest in monogenic targets in the heart, kidney, eyes, ears, muscle, bone/connective tissue, blood as well as neurodegenerative disease in the central nervous system
- Benitec Biopharma's platform is DNA-based RNAi with adeno-associated viral delivery, however different viral delivery platforms are also of interest
- There is also interest in antisense oligonucleotide-based therapy that can be adapted into RNAi-based therapy

Developmental Stages of Interest

- Opportunities at preclinical research phase to Phase I clinical trial are within scope
- Opportunities with in vivo validation (e.g. animal models) are of highest interest, although opportunities with in vitro validation will still be considered

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Benitec Biopharma is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

- Spinout companies
- Technologies
- Centres of excellence
- Academics and expertise
- Research projects

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 1st November 2021 - 11:59 pm GMT

Have any questions? Contact our team at discover@in-part.co.uk

Benitec Biopharma believe their technology has the potential to provide a “one shot” cure for a wide range of diseases that are currently addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options.